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Hypothesis: Is renal allograft rejection initiated by the response Although the focus is allograft rejection, some illustra-
to injury sustained during the transplant process? Allograft tions are taken from models of the immune response
rejection can be caused by numerous factors such as damage against infections because over the course of time, theto the donor kidney during surgical removal or implantation,
immune response evolved, not to reject allografts, butinjury sustained during the transport process between the do-
to defend against infections [10–14]. Thus, the same rulesnor and recipient, and suboptimal allograft perfusion during
the intra- and post-operative period. In cadaveric allografts, govern the immune response against infections and
damage can occur during cold storage, during the transit stage against allografts. In this article, we focus on how the
between donor and recipient, and hemodynamic instability due
response to injury affects the outcome of interactionsto the initial damage that caused its removal from the donor
between CD4 T cells and nonself; however, similar con-(such as brain death or trauma). We hypothesize that rejection
requires recognition of this injury in addition to recognition siderations also govern CD8 T cells and B cells [2, 4].
of alloantigens. If indeed injury proves to be one factor in After reviewing the basic immunology, data are pre-
acute rejection episodes, then therapeutic efforts can be made sented supporting a clinical prediction of the hypothesisto reduce injury during the transplantation process.
that the greater the injury sustained during the transplant
process, the more rejection should occur. Finally, thera-
peutic implications of the hypothesis are discussed.All renal allografts suffer unavoidable injury from the
Injury during the transplant process also affects the allo-transplant process: during surgery to remove the kidney
antigen-dependent and the alloantigen-independent pro-from the donor, when the kidney is transported ex vivo
cesses of chronic “rejection” (chronic allograft nephrop-to the recipient, and during the creation of vascular anas-
athy). Others have previously discussed these issues [6–8]tomoses between the allograft and recipient. Cadaveric
and they are not specifically covered in this review.allografts are further injured by cold storage while in
transit from the donor to the recipient and by the hemo-
dynamic instability associated with the trauma or acute THE HYPOTHESIS
illness, which caused brain death of the donor. In this The hypothesis that rejection is initiated by the re-
article, we discuss the hypothesis that this injury initiates sponse to injury sustained during the transplant process
rejection. In other words, allograft rejection requires two has two major parts. First, it postulates that the recipi-
types of recognition: recognition of specific nonself allo- ent’s immune system recognizes injury to the trans-
antigens and recognition of injury. The hypothesis is an
planted kidney. Second, it postulates that such recogni-
extension of theoretical concepts proposed by Matzinger
tion initiates allograft rejection.
[1]; Medzhitov and Janeway [2]; Ibrahim, Chain, and
Katz [3]; Fearon and Locksley [4], and work demonstra- Recognition of injury
ting an inflammatory response to renal ischemia [5–9].
Traditionally, immunologists studying rejection have
focused on one type of recognition: the specific recogni-
tion of alloantigens. However, recent data indicate thatKey words: transplantation, acute renal failure, T cell, cytokine, chemo-
kine. there are actually three types of immune recognition
(Table 1), one of which is recognition of injury.Received for publication April 8, 1998
Recognition of specific nonself antigens. Most researchand in revised form July 10, 1998
Accepted for publication July 18, 1998 in immunology has been focused on this type of recogni-
tion. It occurs via “conventional” T-cell receptors (TcR) 1999 by the International Society of Nephrology
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Table 2. How the response to injury initiates rejectionTable 1. Three types of recognition that occur during an immune
response: Acute rejection is the result of recognition of specific
Recruit inflammatory cells, including T cells, into the allograft. Thisnon-self antigens plus recognition of injury
occurs by activation of the endothelium to express adhesion molecules
and the production of cytokines and chemokines.(A) Recognition of specific non-self antigens.
Via antibodies produced by conventional B cells.
Promote the traffic of dendritic cells into the allograft and then fromVia the T-cell receptors (TcR) of conventional cells. These T
the allograft to lymph nodes and spleen where naive T cells arecells have TcR consisting of a and b chains, have either CD4
sensitized.or CD8 on their cell surfaces, and require a thymus for their
development. Induce the expression of costimulatory signals to facilitate T cell
(B) Recognition of injury. activation.
Activation of complement.
Regulate T cell differentiation via the activities of natural killer andActivation of the coagulation pathways.
unconventional T cells in the transplant, and via the release of specificActivation of specific transcription factors [such as NF-kB, and
chemokines and cytokines. Unconventional T cells include those withstress activated protein kinases (SAPK)] in response to cellular
both NK and CD4 on their cell surfaces, or have T cell receptorsinjury. These transcription factors activate genes for cytokines,
consisting of gamma delta chains instead of alpha beta chains.chemokines, and endothelial adhesion molecules. Together, prod-
ucts of these genes recruit an inflammatory infiltrate to the site
of injury.
(C) Pattern recognition of pathogenic molecules.
These molecules are released by infectious pathogens, but not
mammalian cells. The receptors recognize the basic biochemical Recognition of injury initiates rejection
pattern of the class of molecule but not specific details. For exam-
A major focus of immunology in the past decades hasple, receptors for endotoxin recognize the basic structure of lipid
A that is a component of all endotoxins, but the receptors do been on the recognition of specific alloantigens during
not recognize specific details of the various endotoxins produced rejection. However, by itself, such recognition is not suf-
by different strains of gram-negative bacteria. This allows a small
ficient to resolve the following two fundamental ques-number of different receptors to recognize a large number of
different pathogenic molecules. tions [1, 3, 16–18]: (a) Should the immune response be
activated? After specific alloantigens on the transplant
are recognized, there may be rejection, tolerance, or
ignorance of the allograft. The hypothesis states that
recognition of injury will determine if there is an activeand antibodies. It includes the recognition of allogeneic
immune response [1, 3, 18]. Injury causes the immuneHLA-A, -B, and -DR on the renal transplant by T cells
system to identify the nonself antigen as the perpetratorthat have antigen receptors (TcR) consisting of two pep-
of the injury and attack the antigen. During an infection,tides, an a and a b chain, that have either CD4 or CD8
the antigen recognized as the perpetrator would be thecell surface molecules, that lack molecules typical of
infectious pathogen. After transplantation, the antigennatural killer (NK) cells and that require a thymus for
would be the alloantigens of the allograft. (b) If thetheir development. Cyclosporine, tacrolimus, and siroli-
immune response is activated, what type of responsemus inhibit the activation of these “conventional” T cells.
should occur? The immune system is not monolithic.This type of recognition also includes the high affinity
Instead, there is a variety of potential responses. Foranti-HLA A and anti-HLA B antibodies, which cause
example, B cells may secrete IgE, IgA, IgM, or comple-hyperacute rejection in patients receiving a second trans-
ment-fixing or non–complement-fixing IgG antibodies.plant [2].
There are also a large number of potential T-cell re-Recognition of injury. Injury occurs during the trans-
sponses. How ischemia may determine which of theseplant process [1]. Recognition of this injury and its contri-
responses is provoked by the allograft will be discussedbution to allograft rejection are a major focus of this
later in this article.article. Tissue injury also occurs during infection and may
contribute to activating the immune response against
infectious pathogens [3]. HOW THE RECOGNITION OF INJURY
INITIATES REJECTIONPattern recognition of pathogenic molecules. This type
of recognition does not contribute to transplant rejec- Rejection requires two types of recognition. The renal
tion. The pathogenic molecules are released by infectious allograft contains nonself antigens that can potentially
agents but not mammalian cells. This type of recognition be recognized by T cells via their TcR. However, as
forms the basis for the “innate” or “natural” response summarized in Table 2, the recognition of the injury of
to infection. A small number of such receptors recognize the transplant process determines if T cells, along with
many different pathogenic molecules by virtue of their other inflammatory cells, will enter the allograft to cause
common biochemical patterns. For example, endotoxin rejection, determines if dendritic cells will migrate to the
receptors recognize the basic biochemical pattern of en- recipient lymph nodes and spleen to sensitize naive T
dotoxin, but not details of particular endotoxins made cells, determines if memory/effector T cells will receive
appropriate costimulation to cause their activation, andby different species of gram-negative bacteria [2, 4, 15].
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may determine the type of T-cell response against the This production of adhesion molecules, cytokines, and
chemokines results after ischemic injury is recognizedallograft. Ischemia is presumed to be the major cause of
renal injury during the transplant process. Much of the by intracellular mechanisms, complement, and the coag-
ulation systems.following discussion focuses on this type of injury.
Intracellular recognition of ischemic injury occurs in
Recognition of injury results in inflammation an in vitro model for ischemia/reperfusion in which cells
are exposed to hypoxia, followed by exposure to super-There are ample data that indicate that injury is recog-
nized and causes inflammation in situations in which oxides generated during the reperfusion phase [19]. This
treatment causes renal endothelial and tubular cells tothere is no recognition of specific nonself antigens, and
there is no pattern recognition of pathogenic molecules activate transcription factors, which include nuclear fac-
tor-kB (NF-kB) [35, 36] and c-jun via stress-activatedmade by infectious agents. Inflammation is a general
response to injury. This includes ischemia/reperfusion protein kinases [37]. These transcription factors then
activate genes that promote inflammation, for example,injury, not only in the kidney, but also in skeletal muscle,
myocardium, liver, and intestine [5, 9, 19–22]. In addi- IL-1a [38], IL-6 [39], cyclooxygenase (COX2) [40], and
endothelial adhesion molecules [41].tion, inflammation also occurs in response to renal injury
caused by toxins [23] and ureteric obstruction [24]. As The alternative pathway of complement recognizes
ischemic injury. This is best described after myocardialdiscussed later in this article, the inflammatory infiltrate
includes T cells and dendritic cells that are critical for ischemia. Ordinarily, there is slow activation of the alter-
native pathway via “C3 tickover,” which is inhibited byinitiating rejection.
To understand how injury results in inflammation, we complement inhibitory proteins DAF (CD55) and pro-
tectin (CD59), thought to be present on all cell surfacesmust first consider the four major steps that occur during
the translocation of leukocytes from the blood, across [42]. Reperfusion injury increases intracellular calcium,
which activates a phosphosphatidylinositol-specific phos-the endothelium, and into the interstitium [25–27]. First,
adhesion molecules appear locally on endothelium that pholipase C. This enzyme cleaves the cell-surface com-
plement inhibitory proteins, and as a result the uninhib-has been activated by signals from nearby injured inter-
stitial cells. Second, leukocytes adhere by weak, revers- ited alternative pathway produces C3a and C5a, which
activate endothelia and recruit an inflammatory infil-ible interactions to P and E selectins, vascular cell adhe-
sion molecule-1 (VCAM-1), and hyaluronate on the trate. The C5-9 membrane attack complex is also pro-
duced, and this stimulates other cells to release IL-8 andsurfaces of activated endothelium. Third, during this
weak adherence, the leukocytes themselves receive acti- platelet-activating factor (PAF), which are chemotactic
and activate endothelia [43]. The importance of comple-vation signals, including chemokines, which change the
conformation of their cell-surface b2 integrins so that ment in injury after myocardial ischemia is illustrated by
the ability of complement inhibitor sCR1 to amelioratethese bind their counterligands on the endothelium. The
b2 integrins on leukocyte cell surfaces are LFA-1, inflammation and also infarct size [44].
The coagulation system also recognizes ischemic injuryMac-1, and VLA-4, which bind to three counterligands
on the endothelial surface: intercellular adhesion mole- to endothelia and promotes inflammation at the site of
injury by activating platelets and monocytes that releasecule-1 (ICAM-1) and ICAM-2, and VCAM-1. The sig-
nals activating the leukocytes may include chemokines PAF, chemokines, and cytokines [45–49].
such as interleukin-8 (IL-8) and monocyte chemo-
Dendritic cells and the activation of naive T cellsattractant protein-1 (MCP-1). Fourth, the leukocyte
moves across the endothelium (diapedesis). The recognition of injury results in inflammation.
Among the leukocytes recruited into the renal transplantIschemic renal injury causes all four of these steps to
occur. Ischemia after temporary clamping of the renal by ischemic injury are dendritic cells (abstract; Penfield
et al, J Am Soc Nephrol 8:663, 1997), which are boneartery induces the expression of adhesion molecules on
endothelia, which would allow translocation of leuko- marrow-derived leukocytes that are critical for rejection
of primary transplants because they are thought to becytes. Inactivating these adhesion molecules by trans-
genic knockout or monoclonal antibodies decreases in- uniquely capable of stimulating naive T cells [50]. Pri-
mary transplants are defined as kidneys placed into recip-flammation and also renal injury [28, 29]. Such ischemia
induces chemokine production [30], and therapy that ients who have not previously been immunized against
the donor antigens either by previous renal allograft ordecreases chemokine production also attenuates injury
[31]. This ischemia also causes the kidney to release by previous blood transfusions.
Naive T cells are those T cells that have not beencytokines that are necessary to activate endothelia [32].
Furthermore, ischemia occurring during syngeneic trans- stimulated by antigen after leaving the thymus. The avail-
able data indicate that most naive T cells cannot migrateplantation induces the production of endothelial adhe-
sion molecules, chemokines, and cytokines [5–9, 33, 34]. into nonlymphoid tissues such as the kidney. Instead,
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they circulate through lymph, blood, and lymph nodes sensitivity type response, or by helping B cells to produce
alloreactive antibody. Second, normal rodents receivingand spleen [26, 27, 51, 52]. According to our current
understanding, in order for naive T cells to be stimulated skin [60, 61], cardiac [62], and renal [63] transplants do
have T cells primed by the indirect pathway. Such T cellsby antigens from the renal allograft, dendritic cells must
carry these antigens from the transplant to the lymph are stimulated in vitro by donor MHC peptides binding
to recipient MHC molecules on recipient antigen-pres-nodes and spleen. There the naive T cells are stimulated
and acquire the adhesion molecules—LFA-1 and VLA 4 enting cells (APCs). In humans, such T cells are associ-
ated with rejection of renal [64] and cardiac [65] allo-—necessary to migrate into the allograft. Consistent with
these ideas, clinical renal biopsies indicate that T cells grafts. Third, injecting rodents with MHC peptides
immunizes T cells via the indirect pathway. These T cellsin rejecting allografts have a memory rather than naive
phenotype [10]. cause accelerated rejection of skin [66, 67], cardiac [68],
and renal [69] allografts. Fourth, in some situations, allo-Infection is a model for the traffic of dendritic cells
into and from injured tissue. This traffic is divided into grafts are rejected despite the removal of donor dendritic
cells prior to transplantation [56, 70–72].four stages. Infected tissues release endotoxin, flt3 ligand
[53], granulocyte macrophage-colony stimulating factor
Ischemic injury and costimulatory signals(GM-CSF), IL-1, tumor necrosis factor-a (TNF-a), and
other molecules that recruit monocytes from the bone After stimulation by dendritic cells in the lymph nodes
and spleen, T cells are also among the inflammatorymarrow, cause them to immigrate into the infected tissue,
differentiate into immature dendritic cells, which ingest cells migrating into the renal transplant in response to
ischemia injury. Effective activation of these T cells inantigens, differentiate into mature dendritic cells, and
then migrate into lymph node and spleen [50]. the renal transplant requires two classes of signals. One
signal is delivered to the TcR, and the other is a costimu-Similar events presumably occur after a kidney is in-
jured during the transplant process [54, 55]. We showed latory or “accessory” signal. If a T cell receives a signal
only via its TcR, in the absence of the costimulatorythat renal ischemia recruits dendritic cells into the in-
jured tissue (abstract; Penfield et al, ibid), as predicted signal, tolerance rather than an active response may oc-
cur. Although there are many costimulatory molecules,by Ibrahim, Chain, and Katz [3]. If ischemic injury occurs
in the donor prior to transplantation, then donor den- including heat stable antigen (HSA) and intercellular
adhesion molecule-1 (ICAM-1) [73], the best understooddritic cells would be recruited into the kidney prior to
harvesting the organ. After transplant, these donor den- are B7-1 (CD80) and B7-2 (CD86). These interact with
CD28 on T cells. Renal ischemia induces the release ofdritic cells would migrate to the recipient lymph nodes
and spleen and sensitize naive recipient T cells via the TNF-a and other cytokines [32]. These induce expression
of B7 in the ischemic kidney [74]. Thus, by inducing“direct pathway” of antigen presentation. The donor
major histocompatibility complex (MHC) on these den- B7, the response to ischemia changes the interaction
between antigen and the TcR into an activating ratherdritic cells would directly interact with recipient T cells
[56]. Ischemic injury occurring after transplantation than a tolerogenic event. Consistent with the importance
of B7 in rejection is the prevention of rejection by agentswould recruit recipient dendritic cells into the transplant,
and these would sensitize via the “indirect pathway.” The that block B7 to prevent rejection [75].
In addition to cytokines, the amount of B7 on the cellrecipient dendritic cells would migrate into the allograft,
ingest donor allopeptides, and migrate to the recipient surfaces of APC (such as renal epithelial, endothelial,
dendritic cells, and macrophages) is also regulated bylymph nodes and spleen where they would present the
donor peptides bound to recipient MHC to the naive CD40 and its ligand CD154 (CD154 is the CD40 ligand
and has the following synonyms: CD40L, gp39, andrecipient T cells. These T cells would then acquire the
cell-surface trafficking molecules necessary to travel to TBAM). Given the importance of B7 as a costimulatory
signal in T-cell activation, its regulation by the CD40-the blood and then into the renal transplant [55, 57].
This “indirect pathway” does initiate acute allograft CD154 system is discussed below. APC have CD40 on
their cell surfaces. When these interact with CD154 onrejection [55]. First, skin grafts from transgenic mice,
which have their class II MHC “knocked out,” are re- T cells, the APC: increase their cell surface expression
of B7; increase their secretion of IL-12, TNF-a, IL-1,jected by mechanisms that require CD41 T cells [58,
59]. The donor transgenic mice have no class II MHC- and chemokines; and generally present antigen more
efficiently to T cells [76, 77]. Furthermore, such APCbearing dendritic cells, and rejection cannot be initiated
by the direct pathway. Rejection must be initiated by direct T-cell differentiation toward a Th1 pathway [78].
In addition to regulating the amount of B7 on APCrecipient dendritic cells via the indirect pathway. The
CD41 T cells may cause rejection by facilitating differen- cell surfaces, CD40 on endothelial cell surfaces regulates
T-cell entry into the transplant. Triggering of this CD40tiation of alloreactive CD81 cytotoxic T-lymphocyte
(CTL), by activating macrophages via a delayed hyper- by interaction with CD154 on T cells would increase
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endothelial expression of adhesion molecules and release brasiliensis. The signature lymphokines of a Th2 re-
sponse are IL-4 and IL-5. IL-5 activates eosinophils,of chemokines [76]. The amount of CD40 on endothelial
cell surfaces after cardiac transplantation is increased by while IL-4 induces B cells to secrete IgE, IgM, and
noncomplementing activating IgG isotypes. IL-4 alsoischemia in the absence of rejection [79], as expected
given the ability of TNF-a and IL-1, produced in re- changes gut physiology such that the helminth is ex-
pelled. Only those strains of mice that mount a Th2sponse to ischemia, to increase CD40 on endothelial cells
in vitro [80]. Thus, ischemia would, by increasing CD40 response to infection are cured. Injections of Th1 lym-
phokines increase susceptibility to infection [91]. In addi-expression on endothelial cells, prime the endothelium
for later interactions with T cells, which would allow tion to their signature lymphokines, both Th1 and Th2
cells produce many lymphokines in common, includingT-cell infiltration into the allograft. The importance of
the CD40-CD154 system in transplantation is illustrated IL-3 and GM-CSF [88, 89].
A major factor in determining which differentiationby the ability of monoclonal anti-CD154 and genetically
engineered blocking agents for CD40 to prevent rejec- program T cells follow during the previously mentioned
infections is the cytokines present when the T-cell anti-tion [81].
An additional effect of renal ischemia in both rodent gen interaction takes place. These cytokines are pro-
duced by NK cells and unconventional T cells, which aremodels [5] and humans [82] is increased class II MHC
on renal tubule cells. The immunological significance of T cells with both NK and CD4 T cell markers and
gamma-delta T cells (note that conventional T cells havethis observation is controversial [83, 84]. On one hand,
some studies indicate that renal tubules do not express TcRs consisting of a and b chains, while gamma-delta
T cells have receptors consisting of gamma and deltaB7 and therefore tolerize rather than activate T cells [85,
86]. On the other hand, other studies indicate that renal chains). Immediately after infection, these cells are acti-
vated by Listeria monocytogenes, Mycobacterium tuber-tubule cells may activate T cells by using a non–B7-
costimulatory signal [87]. culosis, or Mycobacteria leprae [92–95], and they produce
IFN-g and macrophages, which have ingested the bacteria,
Is T-cell differentiation regulated by the inflammatory producing IL-12. In the context of IFN-g and IL-12, CD4
response to ischemia? T cells, which interact with bacterial antigens, differenti-
ate down a Th1 pathway. These Th1 cells then secrete theT cells migrating into the renal transplant may differ-
entiate into T cells, which produce a few of the large lymphokines necessary for an effective response against
these intracellular pathogens. In contrast, after helmin-number of possible lymphokines, such as interferon
(IFN)-g, IL-2, IL-3, IL-4, IL-5, etc. Which differentiation thic infections, mast cells secrete IL-4, which causes naive
T cells to differentiate down a Th2 pathway and producepathway occurs is determined by the initial interactions
between the T cell and antigen [88, 89] and will have a the lymphokines necessary for an effective response
against this parasite. Gamma-delta T cells may directmajor impact on if and how an allograft is rejected.
Although the differentiation of T cells after transplanta- differentiation down either Th1 or Th2 pathways de-
pending on whether they interact with Listeria monocy-tion is not yet well delineated, it is understood in a
number of infectious disease models. Review of these togenes or Nippostrongylus brasiliensis, respectively [96].
These infectious disease models illustrate the impor-models may aid our understanding of transplant rejection
and also allow us to suggest mechanisms whereby the tance of unconventional T cells in regulating the differen-
tiation of CD4 T cells. Natural killer (NK), NK/CD4,initial response to ischemic injury might regulate T-cell
differentiation. and gamma-delta T cells are also found in biopsies early
during allograft rejection [97–99] and may also have aIn several well-described infections, CD4 T cells differ-
entiate into Th1 or Th2 cells. The outcome of infection— regulatory role. The gamma-delta T cells may be re-
sponding to renal tubule cells injured by ischemia be-death or cure—is determined by which response occurs.
For example, the progressive and ultimately fatal lepro- cause they are activated by injured cells in other models.
Thus, some gamma-delta T cells are stimulated by di-matous response to Mycobacteria leprae is associated
with Th2 cells, but the tuberculoid response, which ulti- phosphoglyceric acid and isopentenylpyrophosphate re-
leased by injured cells [100]. Other gamma-delta T cellsmately results in cure, is associated with a Th1 response
[90]. The signature lymphokine produced by Th1 cells are activated by heat shock proteins (hsp) [15] that are
produced by renal epithelial cells after ischemic injuryis IFN-g. This activates macrophages to destroy Myco-
bacteria leprae. IFN-g also regulates B cells to produce [101–107]. After these unconventional T cells are acti-
vated by injured renal cells, they might produce cyto-IgG antibody isotypes, which bind to pathogens and then
promote their destruction by activating complement and kines that regulate the response of conventional T cells
to the transplant as they do in the infectious diseasesby inducing phagocytosis via binding to Fc receptors on
these cells. As another example, a Th2 response protects discussed in the previous paragraph. The potential im-
portance of hsp in regulating rejection is supported byagainst infection by helminths such as Nippostrongylus
Lu et al: Does ischemic injury initiate allograft rejection?2162
the ability of hsp to bind immunosuppressive agents such and no rejection [1]. Unfortunately, this prediction can-
not be tested in a transplant model because it is notas desoxypergualin [108], certain conserved immunosup-
pressive class I MHC peptides [109], and a complex of yet possible to perform a renal transplant without some
damage to the organ during the transplant process. How-proteins that includes the steroid receptor and immu-
nophilins that interact with tacrolimus (FK506), rapa- ever, the prediction may be tested in studies of Listeri-
osis. In this system, injury depends on production ofmycin, and cyclosporine [107, 110]. Furthermore, gam-
ma-delta T cells may respond to injured epithelium by listeriolysin by the bacteria. After listeria are ingested
by macrophages, neutrophils, epithelial, or endothelialproducing growth factors that facilitate tissue repair
[111]. cells, the bacteria produce listeriolysin. This lyses the
phagolysosome. The bacteria thus escape the lysosomalSome T cells will differentiate at the site of infection,
for example into Th1 or Th2 cells. In addition, memory bactericidal environment and replicate in the cytoplasm
[122]. This process injures the host cell. Strains of listeriaT cells, which are already committed to a differentiation
program, may be recruited to a site of inflammation. that do not express listeriolysin and that do not injure
the host cell remain trapped within the phagolysosomeIn a previous section, we discussed the inflammatory
response that resulted from cytokines and chemokines where they are eventually killed. Such strains also do not
induce protective immunity. Only listeriolysin-positivereleased by injured interstitial cells and adhesion mole-
cules expressed by the endothelium in response to injury bacteria injure tissue and only listeriolysin-positive bac-
teria induce protective immunity [123].and to the cytokines. Not only do these molecules recruit
leukocytes to the site of injury, but they also regulate In vitro studies confirm the importance of injury in
eliciting an immune response against listeria. Cells in-which leukocytes are recruited [26]. Th1 versus Th2 cells
may be differentially recruited to sites of inflammation. jured by the listeriolysin-producing bacteria produce cy-
tokines that cause inflammation and initiate immunity. IfTh1 cells bind endothelia expressing P- and E-selectins,
but Th2 cells do not [112]. Th1 and Th2 cells respond the infected cell is an endothelial cell, the injury triggers
expression of adhesion molecules [124]. As discussedto different chemokines. For example, in some studies,
Th1 cells respond to MIP1a, MIP1b, and RANTES, previously, such molecules would cause leukocytes to
migrate to the site of infection and help initiate an im-whereas Th2 cells respond to eotaxin [113, 114].
The differentiation of T cells that facilitate host de- mune response. Similarly, only listeriolysin-positive bac-
teria that injure macrophages cause these cells to secretefense against the particular infections discussed earlier
in this article is well understood and can be divided into IL-12 [125], TNF-a [126], IL-1a , and IL-6 [127]. In
contrast, bacteria that do not produce listeriolysin do notTh1 versus Th2 programs. Other situations, in particular
the T-cell differentiation programs that cause tolerance cause cytokine secretion or increased adhesion molecule
expression by the infected mammalian cell.or rejection after renal transplantation, are not under-
stood [115]. Although in some studies Th1 and Th2 cyto-
kine profiles are associated with renal allograft rejection CLINICAL DATA SUPPORT THE HYPOTHESIS
and tolerance, respectively [116, 117], other studies do
Five sets of clinical observations are consistent withnot confirm these findings [118; reviewed in 119–121].
the idea that rejection is initiated by the inflammatoryThe point of this discussion is that T cells do need
response to ischemic injury sustained during transplanta-to differentiate in order to either reject or tolerate an
tion.allograft. Precisely which differentiation programs occur
(1) Clinical data indicate that there is indeed an in-remain to be elucidated, but are likely to be influenced
flammatory response to ischemic injury in human kid-by the response to allograft injury. The differentiation
neys. Native kidneys with ischemic acute renal failureprogram followed by T cells is likely to be affected by
have mild interstitial inflammation and tubulitis [128].unconventional lymphocytes known to be present in the
After transplantation of renal autografts in dogs andallograft early during rejection, and these unconven-
between human identical twins, biopsies revealed a mildtional T cells may be responding to injured tissue. Fur-
inflammatory infiltrate. There is no rejection in thesethermore, which T cells migrate into the allograft is regu-
situations, and the inflammation is due to injury oc-lated to some degree by cytokines, chemokines, and
curring during the transplant procedure [129].adhesion molecules made in the kidney in response to
(2) If injury initiates rejection, which is ordinarily con-injury.
trolled by immunosuppressive drugs, then severe injury
during the transplantation process should result in a
IS INJURY REQUIRED FOR AN greater incidence of rejection. This type of severe injury
IMMUNE RESPONSE? is a major contributor to post-transplant acute tubular
necrosis (ATN) or acute renal failure. Post-transplantThe most provocative prediction of the hypothesis is
that in the absence of injury, there would be no immunity ATN is also called “delayed function” and is defined as
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Table 3. An increased incidence of rejection is associated with post-transplant acute tubular necrosis (ATN)a in patients
who have not previously received an allograft
Patients with Rejection in patients Rejection in patients
post-transplant with post-transplant with immediate
N Single (S) ATN ATN function
Citation Year patients or multi-(M) center % % %
Ojo [136] 1997 37,216 Multi-center 24% 37% 20% P,0.001
Troppman 134] 1996 298 Single center (all received ALG) 23% 57% 40% P,0.004
Halloran [5] 1997 429 Single center 33% 68% 55% P,0.011
Nicholson [153] 1996 308 Single center 28% 53% 46% P,0.31
Lehtonen [154] 1997 862 Single center 07%b 39% 24% P,0.05
a Post-transplant ATN is defined as the need for at least one dialysis treatment after transplantation
b In this study 7% of the kidneys had delayed function lasting more than 15 days. Those kidneys with shorter duration did not have an increased incidence of
acute rejection compared with kidneys with immediate function.
a requirement for dialysis immediately after transplant, mismatch over 1 HLA and by 1.08 for each additional
12 hours of cold ischemia time [136].followed by a recovery of renal allograft function. Hal-
loran, Aprile and Farewell noted increased acute rejec- Allografts with post-transplant ATN, particularly
those that also experience rejection, have decreasedtions of these allografts, and suggested that severe injury
made renal allografts “more rejectable” [130]. As shown long-term survival compared with cadaveric allografts
with immediate function [135]. As discussed in the pre-in Table 3, a number of other recent studies confirm these
observations in primary kidney transplants. In Table 3, ceding paragraph, increased rejection will decrease allo-
graft survival, but other factors also contribute to theretransplants were excluded because post-transplant
ATN in these patients may be the result of “delayed decreased survival of allografts with post-transplant
ATN [8]. Dialysis may delay the diagnosis of rejection.hyperacute rejection,” which is rare in primary trans-
plants [131]. Two of these studies are particularly con- In a functioning transplant, increases in the serum creati-
nine are indicators that rejection may be present. Thesevincing. Leggat et al’s data have the statistical power of
31,600 primary cadaveric renal transplants drawn from indicators are lost if the patient requires dialysis. The
diagnosis of rejection may, therefore, be delayed andthe U.S. Renal Data System [132]. A potential problem
with such multicenter studies is the possibility that pa- therapy may be less effective. Furthermore, the renal
allograft with post-transplant ATN may have fewer func-tients with post-transplant ATN may have been managed
differently than patients with immediate function. For tioning nephrons even after a recovery from the ATN.
Such transplants will be more susceptible to the progres-example, patients with post-transplant ATN may have
received anti–T-cell antibodies, whereas those with im- sive maladaptive response to nephron loss than trans-
plants that have immediate function and more function-mediate function may have received only cyclosporine
and steroids. Troppmann et al’s study overcomes this ing nephrons [137].
(3) If injury initiates rejection, then less injury duringcriticism [133]. Although there were only 457 patients,
all patients received anti–T-cell antibodies, and initiation transplantation should result in less rejection and a better
outcome. When the three-year survival of 497 living unre-of cyclosporine was delayed irrespective of whether post-
transplant ATN occurred. Besides the presence or ab- lated transplants, 3368 parent-to-child transplants, and
43,341 primary cadaveric transplants were compared, thesence of post-transplant ATN, another measure of injury
to the renal allograft is the serum creatinine at postopera- survival of the living unrelated and parent-to-child trans-
plants was equal to or was much better than the cadaverictive day 10. Patients with a higher serum creatinine at
this time have a higher incidence of acute rejection [134], transplants [138]. The superior survival of the living unre-
lated transplants compared with the cadaveric trans-which is also consistent with the idea that increased early
renal damage makes the kidney “more rejectable.” plants occurred despite the poorer HLA matching of the
living unrelated transplants. A major difference betweenAlthough injury may be one factor, increased HLA
mismatching will also be important in initiating rejection. the living unrelated and the cadaveric transplants was
presumably the hemodynamic instability in the cadaverFor example, of the kidneys with post-transplant ATN,
those with zero HLA mismatches have a better survival donors associated with the acute trauma or illness that
caused brain death and the cold storage time of thethan those with one or more mismatches [135]. Further-
more, long-term prognosis of primary renal allografts cadaver kidney. In contrast, the living unrelated kidney
suffered less injury because it was harvested from adepends not only on cold ischemia time (one determi-
nant of injury), but also on HLA matching. The relative healthy, hemodynamically stable donor and was immedi-
ately transplanted. We propose that less initial injuryrisk of graft failure increases by 1.06 for each additional
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Table 4. Clinical implications of the hypothesis that rejectionresults in less inflammation and that this, in turn, de-
is initiated by the response to injury sustained during the
creases rejection and improves allograft survival. An al- transplant process
ternative hypothesis is that the living donor transplants
Attention to renal perfusion during management of the cadaverichave a greater mass of functioning nephrons than cadav- donor.
eric transplants because the latter are damaged by cold
Minimized cold ischemia time.
ischemia, etc. This attenuates the maladaptive response
Meticulous surgical technique.to nephron loss, which causes progressive renal impair-
Optimize allograft perfusion during the intra- and post-operativement [137]. Our hypothesis and this alternative hypothe-
period by judicious fluid and electrolyte management.sis are not mutually exclusive.
Application of new therapies to prevent ischemic acute renal failureEven during living donor transplantation, the kidney
to transplantation.
still suffers some injury during the process of removal
from the donor and transplantation into the recipient.
Rejection does occur, albeit at a lower rate than cadav-
eric transplantation, and HLA matching is a determinant
In this manuscript, we have reviewed the increasing evi-of allograft survival. The half-lives for haploidentical, 1
dence that indicates that rejection is initiated by thishaplotype matched, and zero haplotype matched are
response to injury. In other words, rejection requires not25.0, 16.0, and 11.9 years, respectively, and the one-year
only recognition of specific nonself antigens, but alsosurvival rates are 96, 92, and 91%, respectively, with a
recognition of injury [1].P , 0.025 when any two groups are compared [139].
If the response to injury is one important component(4) If injury initiates rejection, then therapies that de-
of acute rejection, then major therapeutic efforts shouldcrease injury during transplantation should also decrease
be made to decrease injury during the transplant process.acute rejection. Two such therapies have been reported.
As summarized in Table 4, this includes attention toFirst, injury to the allograft may release toxic oxygen
renal perfusion in the cadaveric donor, minimizing coldmetabolites [19] when the allograft is revascularized and
ischemia time, meticulous surgical technique, and opti-reperfused. In some studies, the number of acute rejec-
mizing allograft perfusion during the intraoperativetion episodes was decreased by the administration of
and postoperative period. Furthermore, transplantationhuman recombinant superoxide dismutase, which should
should take advantage of new research that amelioratesdecrease the amount of these toxic metabolites and de-
renal injury. Such strategies include the use of antibodiescrease renal injury [9, 140–142]. Second, monoclonal an-
to adhesion molecules [28, 143, 146], growth factorstibodies against the adhesion molecules ICAM-1 and
[150], atrial natriuretic peptide [151], and a-melanocyte-LFA 1 should prevent translocation of inflammatory
stimulating hormone [31].cells from blood into the kidney after the injury of trans-
plantation [26]. These antibodies ameliorate ischemic
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